Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
Status:
Recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured
by radiographic response in recurrent high-grade primary brain tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Array BioPharma National Cancer Institute (NCI) Pfizer